HC Wainwright Reaffirms Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

HC Wainwright reissued their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock.

Other equities analysts have also recently issued research reports about the stock. Chardan Capital reissued a "buy" rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research report on Thursday, November 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, February 1st. Leerink Partners decreased their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. Finally, BMO Capital Markets cut shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $32.13.

4D Molecular Therapeutics Stock Up 3.7 %

FDMT stock traded up $0.17 during midday trading on Monday, hitting $4.72. The company's stock had a trading volume of 1,355,669 shares, compared to its average volume of 923,816. 4D Molecular Therapeutics has a 52-week low of $4.41 and a 52-week high of $36.25. The firm has a market capitalization of $218.21 million, a P/E ratio of -1.66 and a beta of 2.81. The firm has a 50-day simple moving average of $5.65 and a 200-day simple moving average of $9.49.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC increased its stake in 4D Molecular Therapeutics by 141.0% in the third quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after purchasing an additional 67,202 shares during the period. Novo Holdings A S increased its stake in 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company's stock valued at $16,215,000 after purchasing an additional 100,000 shares during the period. nVerses Capital LLC acquired a new position in 4D Molecular Therapeutics in the third quarter valued at $40,000. Braidwell LP increased its stake in 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company's stock valued at $13,247,000 after purchasing an additional 855,990 shares during the period. Finally, State Street Corp increased its stake in 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company's stock valued at $22,879,000 after purchasing an additional 37,232 shares during the period. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.